- Home
- SJT vs AVIR Comparison
SJT vs AVIR Comparison
Compare SJT & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SJT
- AVIR
- Stock Information
- Founded
- SJT 1980
- AVIR 2012
- Country
- SJT United States
- AVIR United States
- Employees
- SJT N/A
- AVIR N/A
- Industry
- SJT Oil & Gas Production
- AVIR Medicinal Chemicals and Botanical Products
- Sector
- SJT Energy
- AVIR Health Care
- Exchange
- SJT Nasdaq
- AVIR Nasdaq
- Market Cap
- SJT 269.4M
- AVIR 290.4M
- IPO Year
- SJT N/A
- AVIR 2020
- Fundamental
- Price
- SJT $6.47
- AVIR $2.90
- Analyst Decision
- SJT
- AVIR Hold
- Analyst Count
- SJT 0
- AVIR 1
- Target Price
- SJT N/A
- AVIR $6.00
- AVG Volume (30 Days)
- SJT 193.0K
- AVIR 297.2K
- Earning Date
- SJT 11-13-2025
- AVIR 11-06-2025
- Dividend Yield
- SJT N/A
- AVIR N/A
- EPS Growth
- SJT N/A
- AVIR N/A
- EPS
- SJT N/A
- AVIR N/A
- Revenue
- SJT $42,635.00
- AVIR N/A
- Revenue This Year
- SJT N/A
- AVIR N/A
- Revenue Next Year
- SJT N/A
- AVIR N/A
- P/E Ratio
- SJT N/A
- AVIR N/A
- Revenue Growth
- SJT N/A
- AVIR N/A
- 52 Week Low
- SJT $3.66
- AVIR $2.46
- 52 Week High
- SJT $7.22
- AVIR $4.02
- Technical
- Relative Strength Index (RSI)
- SJT 73.33
- AVIR 37.71
- Support Level
- SJT $5.76
- AVIR $2.78
- Resistance Level
- SJT $6.50
- AVIR $2.94
- Average True Range (ATR)
- SJT 0.22
- AVIR 0.11
- MACD
- SJT 0.07
- AVIR 0.01
- Stochastic Oscillator
- SJT 84.95
- AVIR 43.64
About SJT San Juan Basin Royalty Trust
San Juan Basin Royalty Trust is an energy sector royalty trust in the United States. It owns approximately 75% net profit interest in a large number of natural gas properties in the San Juan Basin of New Mexico. About 98% of the royalties San Juan collects come from natural gas, with the balance coming from oil.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing antiviral therapeutics to improve the lives of patients suffering from serious viral infections. The company is developing its product candidate, bemnifosbuvir, for the treatment of COVID-19, the disease caused by infection with Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) and its variants and also developing bemnifosbuvir in combination with ruzasvir for the treatment of Hepatitis C (HCV).